相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation
Iona Paterson et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2023)
Increasing life expectancy in cystic fibrosis: Advances and challenges
Kimberly A. McBennett et al.
PEDIATRIC PULMONOLOGY (2022)
State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy
Aniello Meoli et al.
PHARMACEUTICALS (2021)
A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators
Elizabeth Marie Gavioli et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2021)
Discovery of CFTR modulators for the treatment of cystic fibrosis
Miqueias Lopes-Pacheco et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Cystic fibrosis in the year 2020: A disease with a new face
Kris De Boeck
ACTA PAEDIATRICA (2020)
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
John McNamara et al.
LANCET RESPIRATORY MEDICINE (2019)
Network Biology Identifies Novel Regulators of CFTR Trafficking and Membrane Stability
Claudia Almeida Loureiro et al.
FRONTIERS IN PHARMACOLOGY (2019)
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
Scott H. Donaldson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR
Ana M. Matos et al.
SCIENTIFIC REPORTS (2018)
Role of CFTR in epithelial physiology
Vinciane Saint-Criq et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease
Dominique Hubert et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Repairing the basic defect in cystic fibrosis - one approach is not enough
Carlos M. Farinha et al.
FEBS JOURNAL (2016)
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Guido Veit et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Deborah M. Cholon et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression
Huihua Zhang et al.
SCIENTIFIC REPORTS (2014)
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael P. Boyle et al.
LANCET RESPIRATORY MEDICINE (2014)
HGF Stimulation of Rac1 Signaling Enhances Pharmacological Correction of the Most Prevalent Cystic Fibrosis Mutant F508del-CFTR
Sonia Moniz et al.
ACS CHEMICAL BIOLOGY (2013)
Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi
Carlos M. Farinha et al.
FEBS JOURNAL (2013)
Hepatocyte growth factor in lung repair and pulmonary fibrosis
Ronald Allan M. Panganiban et al.
ACTA PHARMACOLOGICA SINICA (2011)
Loss of tight junction barrier function and its role in cancer metastasis
Tracey A. Martin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
分享论文
